Genzyme to Reach Normal Cerezyme Supply in Q4

Genzyme expects it can fully supply the worldwide market for its Gaucher’s disease drug Cerezyme in the fourth quarter, another step in its recovery from ongoing manufacturing difficulties. U.S. patients began returning to normal doses in September after a shortage of the drug was caused by manufacturing issues at Genzyme’s Allston, Mass., facility. Cerezyme (imiglucerase) and Fabry disease drug Fabrazyme (agalsidase beta) have been in short supply since 2009 after a viral contamination temporarily shut down the facility and an FDA inspection also found a particulate contamination at the same plant.
Drug GMP Report